1. Home
  2. PROP vs BOLD Comparison

PROP vs BOLD Comparison

Compare PROP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prairie Operating Co.

PROP

Prairie Operating Co.

HOLD

Current Price

$0.42

Market Cap

70.1M

Sector

Finance

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.79

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROP
BOLD
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
70.1M
60.8M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
PROP
BOLD
Price
$0.42
$2.79
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$6.75
$4.00
AVG Volume (30 Days)
1.6M
83.1K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
49.06
32.47
EPS
N/A
N/A
Revenue
$7,939,000.00
N/A
Revenue This Year
$81.83
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
413.59
N/A
52 Week Low
$0.38
$0.96
52 Week High
$2.55
$3.16

Technical Indicators

Market Signals
Indicator
PROP
BOLD
Relative Strength Index (RSI) 35.56 48.14
Support Level N/A $2.74
Resistance Level $0.59 $2.97
Average True Range (ATR) 0.04 0.07
MACD 0.00 -0.02
Stochastic Oscillator 19.28 16.67

Price Performance

Historical Comparison
PROP
BOLD

About PROP Prairie Operating Co.

Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: